Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB0026 in Prevention of RSV LRTI in Infants (Ib/II)
CTR20232147Phase 2Completed
- Sponsor
- Ruiyang Pharmaceutical
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RB0026 in respiratory syncytial virus disease (RSV), pulmonary infection, sponsored by Ruiyang Pharmaceutical. Started Jul 2023; status: completed.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on CTR20232147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232147.